Business Wire

CA-CEPTON-TECHNOLOGIES

16.3.2021 13:02:10 CET | Business Wire | Press release

Share
Barrier1 Systems Partners With Cepton to Deploy State-of-the-art Lidar-based Security and Safety Systems for Global Customers

Cepton, a leading provider of intelligent, lidar-based solutions, today announced a partnership with top perimeter security solutions provider, Barrier1 Systems. Using Cepton’s Helius™ Smart Lidar System , Barrier1 Systems is adding new layers of intelligence to its physical barrier systems to enable the next-generation of early-warning intrusion detection and onsite safety applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316005303/en/

North Carolina-based Barrier1 Systems is working with global customers in the public and private sectors to install innovative new solutions that leverage the unique capabilities of Cepton ’s Helius system, which combines a network of Vista®-P lidar sensors with edge computing and advanced perception software, to deliver real-time, anonymized, 3D object detection, classification, tracking and velocity. The partnership demonstrates the versatility of Cepton’s lidar technology, and how smart lidar solutions are increasing security and safety in various types of public and private commercial spaces and facilities.

In one customer application, Barrier1 Systems has combined its barrier control systems with Helius to monitor the speed and direction of vehicles approaching entrance or exit points. If a vehicle exceeds a certain speed limit within a specified range, the system will flag it as a potential intrusion attempt and trigger an alert to the central system for further actions. By classifying vehicle travel direction, it can also guard against incoming threats through outbound roadways.

Deployments like the one above utilize the Cepton Vista lidar’s long range, high resolution imaging capabilities, and the Helius solution’s real-time, 3D information on object dimensions, locations and velocities. For example, Barrier 1 Systems uses Helius to detect and classify vehicles at 150 meters and keep track of their velocities to help diagnose whether there is a potential breach. The object information from Helius is much more accurate than from radars, thereby minimizing false positives and false negatives.

Barrier1 Systems has also deployed Cepton’s Helius system to help ensure facility security and onsite safety. For instance, a network of Vista-P90 lidar sensors has been installed at customer inventory sites to monitor access points. Helius generates useful information such as whether a detected object is a vehicle or a person, how fast it is moving and whether it is in a pre-defined exclusion zone. As lidars perform 24/7 under many weather and lighting conditions challenging for cameras, this helps facility managers continuously ensure property security and worker safety. Facilities can utilize the smart lidar data to flag potential accidents and breaches of access control.

Speaking of the partnership, Baxter Matthews, Vice President of Security Projects at Barrier1 Systems, said: “Cepton’s lidar technology and perception solution have allowed us to unleash a new set of innovations and capabilities when it comes to security and safety, which is critical given the range of threats and challenges faced today in both public and private spaces. The simplicity of installation of Cepton’s solution makes it easy for us to deploy and scale up quickly. Further, the anonymous nature of the lidar images, combined with their high accuracy, enables significant advancements in the state of the art for security and safety. A major customer liked the advantages of our solution so much that they want to do a nationwide implementation at all of their sites, which is incredible. What’s exciting is that we are just scratching the surface of what is possible because there are many untapped applications – in the perimeter security industry and beyond – where customers see tremendous potential for solutions arising from our partnership with Cepton.”

Dr. Jun Pei, Cepton’s co-founder and CEO, added: “Beyond its well-known role in the automotive industry, lidar is a versatile technology that enables a whole new level of safety and autonomy in many other applications. Our partnership with Barrier1 is a testament to this. We have designed our MMT®-based lidar solutions with customers’ perception needs in mind, and for security and safety solutions like the ones developed by Barrier1, we have focused on delivering a superior combination of accuracy, reliability and scalability. We look forward to continuing our work with Barrier1 to expand the use cases for lidar globally, by enabling enhanced safety and security solutions using lidar intelligence.”

About Cepton Technologies, Inc.

Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.

Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .

About Barrier1

Barrier1 Systems, LLC (Barrier1 Systems) provides state-of-the-art robust physical barriers and security solutions using innovative products with unique capabilities that meet the customer’s site-specific needs and requirements. In the past 17 years, more than 4500 of our crash rated barrier systems have been fielded in 13 countries.

Barrier1 Systems employs expertise in engineering, welding and metal works, controls & alarms, electronics, power systems, programming, manufacturing, and installation. The company was founded in 2002. Barrier1 Systems does engineering and direct manufacturing for its products and provides post-installation support. For more information about Barrier1 visit www.barrier1.us .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye